|Bid||0.0000 x 1300|
|Ask||0.0000 x 1000|
|Day's Range||4.1400 - 4.2678|
|52 Week Range||3.1300 - 8.7300|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.96|
REHOVOT, Israel , Sept. 26, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) , a regenerative medicine company, today announced financial results for the second quarter ended June 30, 2019 and provided an ...
REHOVOT, Israel, Sept. 9, 2019 /PRNewswire/ -- CollPlant (CLGN) (the "Company"), a regenerative medicine company, announced it has closed on a total of $5.5 million in convertible loans. A group of U.S. accredited investors with deep experience in the 3D printing industry purchased $3.5 million of the convertible loans, and the Company's largest shareholder, Ami Sagi, purchased $2.0 million of the convertible loans, through a non-brokered private placement. An additional $1.0 million investment will be made by Ami Sagi following the execution of a license and/or a co-development agreement between CollPlant and a strategic business partner, if such were to occur.
REHOVOT, Israel, Sept. 5, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced that Yehiel Tal, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte New York Palace Hotel in New York on Tuesday, September 10th, 2019 at 1:45 pm EDT. Mr. Tal will provide an overview of the Company's business, including in the fields of medical aesthetics, breast implants and 3D bioprinting of life saving organs. CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics.
REHOVOT, Israel, Sept. 3, 2019 /PRNewswire/ -- CollPlant (CLGN) (the "Company"), a regenerative medicine company, announced it has entered into definitive agreements for up to $6.5 million funding in convertible loans. The capital raise is by way of a non-brokered private placement with Ami Sagi, the Company's largest shareholder, and U.S. accredited investors with many years of deep experience in 3D printing. Under the terms of the transaction, the initial closing with Mr. Sagi occurred on September 3 2019 where Mr. Sagi funded the Company with $2.0 million.
NEW YORK, Aug. 19, 2019 -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a.
REHOVOT, Israel, Aug. 5, 2019 /PRNewswire/ -- CollPlant (CLGN) (the "Company"), a regenerative medicine company, announced today that it is developing 3D bioprinted implants for regeneration of breast tissue and has successfully produced first prototypes. The implants will be comprised of CollPlant's proprietary type I recombinant human collagen and additional materials. Loaded with fat cells taken from the patient, these implants are intended to promote breast tissue regeneration.
REHOVOT, Israel, June 20, 2019 /PRNewswire/ -- CollPlant (CLGN) (the "Company"), a regenerative medicine company, announced today that its corporate name has changed from "CollPlant Holdings Ltd." to "CollPlant Biotechnologies Ltd." effective on the opening of trading on June 21, 2019. The Company's ADSs will continue trading on the Nasdaq Capital Market under the same ticker symbol "CLGN". "This corporate rebranding, including our name change and new logo, effectively reflects the strategic shift in our business, and the high value opportunities we are pursuing in the field of regenerative medicine," said Yehiel Tal, CollPlant Biotechnologies CEO.
REHOVOT, Israel, June 4, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced that the results from a clinical study conducted with its VergenixFG advanced wound care product will be presented at the 29th Conference of the European Wound Management Association (EWMA). It is one of the largest wound conferences in the world, gathering the European and international wound management communities with the common goal of improving patient wound care. On Friday June 7, 2019, from 10.30 AM - 11.30 AM, Dr. Eyal Shapira from the department of Plastic Surgery, Assaf Harofeh Medical Center, Israel, will present clinical results published in Wounds, a peer reviewed journal focused on wound care and wound research.
REHOVOT, Israel, May 30, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced financial results for the first quarter ended March 31, 2019 and provided an update on the Company's business developments. The Company ended the first quarter of 2019 with $3.7 million in cash and cash equivalents. Comprehensive loss for the first quarter of 2019 was $2.0 million on a GAAP basis, or adjusted comprehensive loss of $1.2 million, on a non-GAAP basis.
REHOVOT, Israel, May 28, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced that Dr. Nadav Orr, the Company's Vice President for R&D, presented the utilization of CollPlant's recombinant human collagen (rhCollagen) in the field of 3D Bioprinting tissues and organs at the Annual Meeting of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) European Union Chapter in Rhodes, Greece on Monday, May 27, 2019. At the session dedicated to bioartificial organs, Dr. Orr demonstrated the unique properties of CollPlant's BioInks which are formulated and optimized for 3D Bioprinting of tissues and organs. The presentation is titled, "Recombinant Human Type I Collagen Compositions for 3D-Bioprinting of Tissues and Organs".
REHOVOT, Israel, May 22, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, has launched a new HQ and R&D center in Israel. CollPlant is developing, manufacturing and commercializing products for tissue repair and organ manufacturing from its proprietary rhCollagen (recombinant human collagen). Collagen, the most abundant protein in humans and mammals, is commonly found in connective tissues such as tendons, skin, blood vessels and bones.
The published article reports results from a study in non-human primates for bone regeneration using a receptor optimized chimera version of BMP-2/BMP-6/activin A delivered in a composite matrix formulated with CollPlant's rhCollagen and ceramic granules. The study results demonstrate the potential for a new treatment that is far superior to the current standard of care in terms of both efficacy and safety. "We believe our rhCollagen is the ideal building block for scaffolds used in regenerative medicine applications, including orthobiologics in both hard and soft tissue repair, 3D bioprinting of tissues and organs, medical aesthetics, and advanced wound care," concluded Mr. Tal.
The ThinkEquity Conference brings together companies in the technology, healthcare, finance, and energy industries with institutional and accredited investors. ThinkEquity is a division of Fordham Financial Management, Inc. "We look forward to presenting to the New York investment community our key activities and latest developments at CollPlant, including medical aesthetics and the collaboration with United Therapeutics for 3D Bioprinting of solid organs for human transplant," stated CollPlant CEO, Yehiel Tal.
- Q4 revenues of $4.2 million with net income of $1.0 million - $4 million revenue from the United Therapeutics license agreement in Q4 - Company expands its aesthetics medical products development into ...
NESS ZIONA, Israel, March 18, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced that it has renewed its exclusive distribution agreement with Arthrex for Vergenix™STR for the treatment of tendinopathy. The original distribution agreement, which commenced in December 2016, is now extended through December 31, 2020, with Arthrex serving as the exclusive distributor of CE Marked Vergenix™STR in Europe, the Middle East, India and certain African countries. Vergenix™STR is an injectable gel comprised of cross-linked bioengineered recombinant human type I collagen, rhCollagen, combined with autologous platelet-rich plasma (PRP).
NESS ZIONA , Israel, March 11, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced results from a clinical study conducted with its VergenixFG wound care product. The results were published in Wounds, a peer-reviewed journal focusing on wound care and wound research. The paper titled, "A Novel Recombinant Human Collagen-based Flowable Matrix for Chronic Lower Limb Wound Management: First Results of a Clinical Trial," presents data from a previously reported independent study conducted by physicians at several wound care medical clinics and hospitals in Israel. The advanced wound care treatment market was estimated at $8.2 billion in 2017, with non-healing chronic ulcers posing a significant health concern and economic burden.
NESS ZIONA, Israel, Feb. 19, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced its production facility in Rehovot, Israel has received DEKRA (European Union Notified Body) Certification, for the manufacturing and purification of its recombinant human collagen, rhCollagen. The Rehovot production facility is now covered by the current CollPlant ISO13485:2016 certification. "DEKRA approval of our production facility is an important milestone enabling us to produce and supply our rhCollagen for our BioInk formulations used in organ manufacturing such as lungs, and for dermal fillers we develop for the medical aesthetics market.
NESS ZIONA, Israel, Feb. 4, 2019 /PRNewswire/ -- CollPlant (CLGN), a regenerative medicine company, today announced that Jonathan M.N. Rigby has been appointed as Chairman of the Board of Directors effective immediately. Mr. Rigby brings to CollPlant over 28 years of experience in the pharmaceutical, biopharmaceutical, medical device and drug delivery industries. "We are delighted to welcome Jonathan as Chairman of our Board at this pivotal time for CollPlant.
CollPlant plans to pursue FDA regulatory approval in U.S. CollPlant (CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced a clinical trial published regarding its Vergenix™STR in the treatment of tennis elbow. The peer reviewed paper titled, "First clinical experience with a new injectable recombinant human collagen scaffold combined with autologous platelet-rich plasma for the treatment of lateral epicondylar tendinopathy (tennis elbow)" was published in the Journal of Shoulder and Elbow Surgery.
NESS ZIONA, Israel , Nov. 29, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant ...
NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CollPlant (CLGN) today announced the closing of a worldwide exclusive license, development and commercialization agreement with United Therapeutics Corporation (UTHR) for 3D bioprinted lung transplants. As previously announced, CollPlant granted United Therapeutics, through its wholly owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, an exclusive license to its technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants throughout the universe. CollPlant will manufacture and supply BioInk for a few years to meet development process demand, and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.
CollPlant (CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced that management will be ringing the Nasdaq Stock Market Opening Bell on Thursday, November 8, 2018. "We look forward to ringing the Nasdaq Stock Market Opening Bell having recently transitioned to exclusively traded on the Nasdaq. CollPlant is increasing its activities in the U.S. and recently we announced our agreement with US-based United Therapeutics, for the use of our rhCollagen-based BioInk technology to manufacture lung transplants using 3D bioprinters," stated Yehiel Tal, CollPlant's Chief Executive Officer.
NESS ZIONA, Israel, Oct. 28, 2018 /PRNewswire/ -- CollPlant (NASDAQ:CLGN, TASE:CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen (recombinant human collagen) technology for tissue repair products, today announced that as from Tuesday, October 30, 2018, the Company's ordinary shares and Series I and Series K Warrants will no longer trade on the Tel-Aviv Stock Exchange (TASE). All trading of ordinary shares will migrate exclusively to the Nasdaq Capital Market in the US under the Company's American Depositary Shares (ADSs) program.